AARON ROSENBERG: Open Payments
NPI 1306237417 · MEQUON, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 24 payments from 11 companies in 2025. Trend: 2023 $5,275 · 2024 $716 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $95 |
| Orexo US, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Indivior Inc. | 2 | $73 |
| Lilly USA, LLC | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Biogen, Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $18 |
Products named: Zubsolv, TRINTELLIX, SUBLOCADE, MOUNJARO, REXULTI, CAPLYTA, XIFAXAN, LEQEMBI.
Industry payments across WI — which companies pay providers there.
